BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:e18196de7ce61cd834f73168a9a33d18
ORGANIZER:registration@iasusa.org
DTSTAMP:20261026T145514Z
LOCATION:
SUMMARY:Update on Tuberculosis/HIV Coinfection: Across the Spectrum From Latent Infection Through Drug-Susceptible and Drug-Resistant Disease
DESCRIPTION:[vc_row][vc_column][vc_column_text]\n\nOverview\n\nAssessment of Needs\nThis webinar will review the landscape of tuberculosis (TB) and HIV coinfection across the disease spectrum\, from latent infection to drug-susceptible and drug-resistant disease. Recent advances include TB preventive therapy for 1 month\, which is safe and effective\, and a 4-month regimen\, after 40 years of a 6-month treatment for drug-susceptible disease\, has proved successful. Equally important\, more effective and tolerable shorter course regimens for highly drug-resistant TB have been identified.\nLearning Objectives\nOn completion of this webinar\, learners will be able to:\n\n 	Describe the current epidemiology of tuberculosis (TB)\n 	Describe recent advances in shorter regimens for TB prevention\n 	Identify the optimal regimen for treatment of drug-susceptible TB\n 	Describe recent advances in treatment of patients with drug-resistant TB\n\nRegistration\nWho Should Attend\nThis webinar is designed for clinical decision makers who are actively involved in HIV care and research\, including physicians\, physician assistants\, nursing professionals\, pharmacists\, and other health care professionals.\n\nIndividual registration is required in order to receive CME credit or a certificate of participation.\n\nRegistration closes on Tuesday\, November 16\, 2021\, 9:00 AM (PT).\n\nCertificates will be available after the completion of the evaluation and claim form.\n\nFor more information or questions\, please contact the registration department at registration@iasusa.org or 415-544-9400.\nConflicts of Interest\nIn the interest of maintaining the independence of its continuing medical education (CME) activities\, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg\, faculty\, Scientific Leadership Board\, Governance Board\, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  \n\nThe Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as "those whose primary business is producing\, marketing\, selling\, re-selling\, or distributing healthcare products used by or on patients.” \n\nIAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.\n\n\nPresenter Disclosure\n\nDr Swindells has received research grants paid toher institution from ViiV Healthcare. (Updated 11/16/21)\nPlanner/Reviewer\nPlanner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 11/16/21)\n\nPlanner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 11/16/21)\n\n\n\n\nContinuing Education Credits\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nABIM MOC Points\nSuccessful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA\, the CME activity provider\, will submit your participant information (eg\, name\, date of birth\, activity credits earned\, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.\nNursing Credits\nEducational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association\, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.5 hours of continuing nursing education.\n\nEducational Review Systems is also approved for nursing continuing education by the state of California\, the state of Florida and the District of Columbia.\n\n\nPharmacy Credits\nEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.5 contact hours (0.15 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event\, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.\nUAN  # 0761-9999-21-332-L01-P\n\n\n\nGrant Support\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from commercial companies. Per IAS–USA policy\, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.\n\nPLATINUM SUPPORTERS\n\nGilead Sciences\, Inc.\nMerck &amp\; Co.\, Inc.\nViiV Healthcare\n\nSILVER SUPPORTER\n\nJanssen Therapeutics\n\nBRONZE SUPPORTER\n\nTheratechnologies Inc.\nFrequently Asked Questions\nView our list of FAQs about attending a webinar.\n\nFurther Questions?\nPlease contact the registration department at registration@iasusa.org or 415-544-9400.\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
STATUS:CONFIRMED
CATEGORIES:Webinars
URL;VALUE=URI:https://www.iasusa.org/events/webinar-2021-swindells/
DTSTART:20211116T180000Z
DTEND:20211116T191500Z
END:VEVENT
END:VCALENDAR